Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution
Ramon Andrade de Mello(Universidade Nove de Julho), José Dinis(Instituto Português de Oncologia Francisco Gentil), Filipa Moreira(Universidade do Porto), Sandra Gerós(Instituto Português de Oncologia Francisco Gentil), Marcos Pantarotto(Instituto Português de Oncologia Francisco Gentil), Isabel Avezedo(Instituto Português de Oncologia Francisco Gentil)
Cited by 53
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
|Journal of Clinical Oncology|2011|221
Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
|Annals of Oncology|2017|90
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
|Cancer Chemotherapy and Pharmacology|2014|87